Influenza drugs are medications created to either prevent or treat the flu, a contagious respiratory sickness. They include antiviral drugs that focus on the flu virus itself, as well as drugs that help relieve symptoms like fever, cough, and congestion. These medications are essential for handling and lessening the impact of flu outbreaks, particularly during times of widespread transmission or pandemics.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-influenza-drug-market
Data Bridge Market Research analyzes that the Global Influenza Drug Market is expected to grow at a CAGR of 6.5% in the forecast period of 2024 to 2031 and is expected to reach USD 14.22 billion by 2031 from USD 8.73 billion in 2023. The influenza A segment is projected to propel the market growth due to its seasonal epidemics and occasional pandemics, resulting in a significant disease burden worldwide.
Key Findings of the Study
Government Initiatives and Vaccination Programs
Increased government initiatives and expanded vaccination programs play a pivotal role in driving growth within the influenza drug market by fostering the stimulating demand. As governments worldwide prioritize public health through comprehensive immunization strategies, pharmaceutical companies specializing in influenza drugs stand to benefit significantly. By actively participating in government initiatives, these companies gain access to lucrative contracts and procurement opportunities for supplying vaccines to national immunization programs. Moreover, engagement in vaccination programs allows pharmaceutical firms to showcase the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility. As governments increasingly prioritize preparedness against seasonal influenza outbreaks and potential pandemics, the demand for innovative vaccines and therapeutics continues to rise. Companies that actively collaborate with government agencies, provide reliable supply chains, and demonstrate commitment to public health objectives are poised to capitalize on this growing market demand. By leveraging government partnerships and actively participating in vaccination programs, pharmaceutical companies can not only contribute to the global fight against influenza but also drive sustainable growth and expansion within the influenza drug market. . Governments also focusing on campaigns, emphasizing the importance of vaccination and adherence to prescribed treatment regimens, further driving the market's growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Type (Influenza A, Influenza B, And Influenza C),Treatment (Quadrivalent, Trivalent, Bivalent, And Monovalent),Route Of Administration (Oral, Intramuscular, Intradermal, Intranasal, And Intravenous), Age (Pediatrics And Adults), End User (Hospitals, And Home Care),Distribution Channel (Direct Tenders And Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa
|
|
Market Players Covered
|
GSK plc. (U.K.), Sanofi S.A. (U.S.), CSL (Australia), Astrazeneca Plc (U.K.), F. Hoffmann-La Roche Ltd (Switzerland) , Abbott (U.S.), Amneal Pharmaceuticals LLC. (U.S.), AbbVie Inc. (U.S.), BioCryst Pharmaceutucals, Inc. (U.S.), Lupin (India), Zydus Pharmaceuticals, Inc. (U.S.), Macleods Pharmaceuticals Ltd. (India), Viatris Inc. (U.S.), DAIICHI SANKYO COMPANY (Japan), LIMITED, Cipla Inc. (India), Shionogi & Co., Ltd. (Japan) , Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), and NATCO Pharma Limited (India), and Alvogen (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis
Global influenza drug market is segmented into six notable segments based on type, treatment, route of administration, age, end user, and distribution channel.
- Based on type, the market is segmented into Influenza A, Influenza B, and Influenza C.
In 2024, the influenza A segment of the type segment is expected to dominate the market.
In 2024, the influenza A segment is expected to dominate the market with a market share of 47.73% due to due to their higher mutation rate, wider host range, pandemic potential, increased severity of illness, and the need for more complex vaccination strategies to control outbreaks.
- Based on treatment, the market is segmented into vaccines and drugs.
In 2024, the vaccines segment of the treatment segment is expected to dominate the market
In 2024 , the vaccines segment is expected to dominate the market with a market share of 87.23% due to its pivotal role in preventing illness, reducing transmission, and addressing public health concerns associated with seasonal outbreaks and potential pandemics.
- Based on route of administration, the market is segmented into oral, intramuscular, intradermal, intranasal, and intravenous. In 2024, the oral segment is expected to dominate the market with a market share of 45.04%
- Based on age, the market is segmented into pediatrics and adults. In 2024, pediatrics segment is expected to dominate the global influenza drug market with a market share of 50.83%
- Based on end user, the market is segmented into hospitals, and home care. In 2024, hospitals segment is expected to dominate the global influenza drug market with market share of 72.62%
- Based on distribution channel, the global influenza drug market is segmented into direct tender and retail sales. In 2024, the direct tender segment is projected to dominate in the global influenza drug market with the largest market share of 56.34%
Major Players
Data Bridge Market Research recognizes the following companies as the major influenza drug market players in the market that include GSK plc. (U.K.), Sanofi S.A. (U.S.), CSL (Australia), Astrazeneca Plc (U.K.), F. Hoffmann-La Roche Ltd (Switzerland).
Market Development
- In November 2023, AstraZeneca has announced a partnership and investment deal with Cellectis, a clinical-stage biotech company, to speed up the development of new therapies in areas with significant unmet medical needs such as oncology, immunology, and rare diseases. This collaboration will allow AstraZeneca to utilize Cellectis' gene editing technologies and manufacturing capabilities to create innovative cell and gene therapy products, enhancing AstraZeneca's portfolio in this field
- In November 2023, Viatris Inc. has announced its participation in the Jefferies London Healthcare Conference in London, UK. Participating in the Conference will provide Viatris Inc. with an opportunity to showcase its products and innovations, network with industry leaders, and potentially attract investors, ultimately contributing to its growth and market presence.
- In June 2023, GSK plc. and BELLUS Health Inc. announced today that GSK has finalized the acquisition of BELLUS, a biopharmaceutical company dedicated to improving the lives of patients with refractory chronic cough (RCC). This acquisition will enhance GSK's portfolio by adding BELLUS's expertise in refractory chronic cough (RCC) treatment, strengthening its position in addressing unmet medical needs in this area.
- In November 2022, CSL has announced that its subsidiary, CSL Seqirus, has signed a collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc to utilize their advanced self-amplifying mRNA (sa-mRNA) vaccine platform technology in the later stages of development. This collaboration will enable CSL Seqirus to leverage Arcturus Therapeutics' advanced sa-mRNA vaccine platform technology, potentially enhancing CSL's vaccine development capabilities.
- In January 2022, Natco Pharma Limited has recently announced the signing of a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) in Switzerland. The MPP had previously acquired the license from Merck Sharp & Dohme Corp. (MSD) in the USA for the same purpose. This agreement with the Medicines Patent Pool will enable Natco Pharma Limited to expand its access to important medicines and enhance its ability to provide affordable healthcare solutions to a broader population.
Regional Analysis
Geographically, the countries covered in the global influenza drug market report are the U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and rest of Middle East and Africa
As per Data Bridge Market Research analysis:
North America is the dominant and fastetst growing region in the global influenza drug market during the forecast period
North America is expected to dominate the market due to has a well-established healthcare infrastructure and robust vaccination programs, driving high demand for influenza drugs. Additionally, the prevalence of influenza outbreaks, coupled with the region's large population, contributes to sustained market growth. Furthermore, North America is home to major pharmaceutical companies with significant investments in influenza research and development, leading to the introduction of innovative therapies and treatments. Lastly, stringent regulatory standards and high healthcare spending in North America foster a conducive environment for market expansion and adoption of new influenza drugs.
For more detailed information about the global influenza drug market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-influenza-drug-market
